10:15–10:30 am | Cerebral consequences of hypertension and Nemo deletion in brain endothelial cells in mice
Marietta Zille (Vienna, Austria)

10:30–10:45 am | Particulate Matter 2.5 Temporally Increases Human Brain Microvascular Endothelial Inflammation and Decreases Barrier Proteins In A Dose Dependent Manner
Saema Ansar (Lund, Sweden)

10:45–11:00 am | Targeted Nanocarrier-Delivered GSB-106 Dipeptide Mimetic of Brain-derived Neurotrophic Factor Enhances Neurogenesis and Blood-Brain Barrier Integrity
Lene-Marlen Wessel (Lund, Sweden)

11:00–11:15 am | Thromboembolic Stroke Alters Claudin-5 Isoform Expression Correlating to Increased Cerebral Edema and Decreased Neurological Function
Trevor Wendt (Lund, Sweden)

11:15–11:30 am | The α5 integrin inhibitor ATN-161 alleviates blood-brain barrier disruption and neuroinflammation associated with SARS-CoV-2 infection
Meenakshi Umar (New Orleans, USA)

11:30–11:45 am | Pharmacological inhibition of plasma kallikrein stabilizes the blood-brain barrier and promotes regeneration after ischemic stroke
Steffen Haupeltshofer (Essen, Germany)

01:30–01:45 pm | Translating oedema extension distance by MRI into a rodent model of ICH
Mary Newland (Manchester, UK)

01:45–02:00 pm | MRI Volumetric Analysis: Secondary Neurodegeneration is Evident at 1 and 6 Months Following Stroke in a Clinically-Relevant Ovine Model
Renee Turner (Adelaide, Australia)

02:00–02:15 pm | 2-Deoxy-D-glucose MRI of impaired brain metabolism after experimental stroke
Philipp Boehm-Sturm (Berlin, Germany)

02:15–02:30 pm | Tract masks for refined analysis of diffusion properties in motor tracts related to functional recovery after stroke in mice
Aref Kalantari (Köln, Germany)

02:30–02:45 pm | Multimodal imaging following ischemia and r-tPA treatment in fully awake mice: a new hope for theranostics of stroke
Myriam Abioui-Mourgues (Caen, France)

02:45–03:00 pm | Consequence of Early and Late Thrombolysis following Ischemic Stroke on Brain Metabolic Profiles Evaluated by 9.4 T MR Spectroscopy
Henrik Andersson (Lund, Sweden)

03:30–03:45 pm | Enhancer RNAs as modulators of the post-stroke chromatin landscape and pathophysiology
Ashutosh Dharap (Tampa, USA)

03:45–04:00 pm | Developing and validating Serine Gamma Peptide Nucleic Acid (sγPNA)-based miR-141-3p Inhibitors for Treatment of Ischemic Stroke
Rajkumar Verma (Farmington, USA)

04:00–04:15 pm | Development of a brain-accessible peptide containing neurotrophin receptor TrkB-T1 sequences that reduces reactive astrogliosis and leads to stroke neuroprotection
Lola Ugalde-Triviño (Madrid, Spain)

04:15–04:30 pm | Micro-RNA Alterations in Post-Stroke Brain Following Physical Exercise in Mice
Marta Klimczak (Barcelona, Spain)

04:30–04:45 pm | The miRNAs miR-3609 and miR-941, associated with cryptogenic stroke functional outcome, regulate αβ-crystallin expression
Guillem Cañellas-Calafat (Palma, Spain)

04:45–05:00 pm | Circular RNA circKlhl2 modulates TBI response influencing the BDNF pathway
Marica Pagliarini (Ulm, Germany)